Barber Glen G - OmicsDI

Previous page
1 / 1
You're on page 1
Next page

Sort by:

Relevance

Page size

Gene expression profiling of dsDNA90 or ssDNA90 stimulated Mouse Embryonic Fibroblasts

Gene expression analysis of wild type, STING knock-out and STAT1 knock-out Mouse Embryonic Fibroblasts (MEFs) stimulated with 90-mer dsDNA or 90-mer ssDNA. Genes whose expression that are affected by cytosolic DNA in a STING dependent manner will be identified and signaling pathways regulated by STI...

ORGANISM(S): Mus musculus

2013-01-15 | E-GEOD-43481 | biostudies-arrayexpress

Cyclic-Di-Nucleotides Trigger ULK1 (ATG1) Phosphorylation of STING to Prevent Sustained Innate Immune Signaling

Activation of the STING (Stimulator of Interferon Genes) pathway by microbial or self-DNA, as well as cyclic di nucleotides (CDN), results in the induction of numerous genes that suppress pathogen replication and facilitate adaptive immunity. However, sustained gene transcription is rigidly prevente...

ORGANISM(S): Mus musculus

2013-10-10 | E-GEOD-51199 | biostudies-arrayexpress

Inflammation-Driven Carcinogenesis is Mediated through STING [skin]

Chronic stimulation of innate immune pathways by microbial agents or damaged tissue is known to promote inflammation-driven tumorigenesis by unclarified mechanisms1-3. Here we demonstrate that mutagenic 7,12-dimethylbenz(a)anthracene (DMBA), etoposide or cisplatin induces nuclear DNA leakage into th...

ORGANISM(S): Mus musculus

2014-05-31 | E-GEOD-57604 | biostudies-arrayexpress

Plasma AR Alterations and Timing of Intensified Hormone Treatment for Prostate Cancer: the STAMPEDE Phase 3 Randomized Clinical Trial.

Not available

S-EPMC11869088 | biostudies-literature

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.

Not available

S-EPMC4800035 | biostudies-literature

Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol.

Not available

S-EPMC12303861 | biostudies-literature

Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial.